556,235 Shares in Cabaletta Bio, Inc. $CABA Bought by Simplify Asset Management Inc.

Posted by George Bondi on Oct 29th, 2026

Simplify Asset Management Inc. acquired a new position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 556,235 shares of the company’s stock, valued at approximately $1,068,000.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Cabaletta Bio in the second quarter worth about $33,447,000. Jennison Associates LLC increased its position in shares of Cabaletta Bio by 0.7% in the first quarter. Jennison Associates LLC now owns 8,970,578 shares of the company’s stock worth $24,131,000 after acquiring an additional 64,879 shares in the last quarter. Opaleye Management Inc. increased its position in shares of Cabaletta Bio by 180.0% in the second quarter. Opaleye Management Inc. now owns 3,863,800 shares of the company’s stock worth $12,016,000 after acquiring an additional 2,483,800 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Cabaletta Bio by 33.8% during the first quarter. Renaissance Technologies LLC now owns 2,036,663 shares of the company’s stock valued at $5,479,000 after acquiring an additional 514,080 shares during the period. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Cabaletta Bio during the second quarter valued at approximately $2,852,181.

Cabaletta Bio Trading Up 4.5%

NASDAQ:CABA opened at $1.52 on Thursday. The business’s fifty day moving average price is $2.37 and its 200 day moving average price is $2.85. The firm has a market capitalization of $257.70 million, a price-to-earnings ratio of -0.97 and a beta of 3.48. Cabaletta Bio, Inc. has a 1-year low of $1.32 and a 1-year high of $4.23.

Cabaletta Bio (NASDAQ:CABA – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. Equities analysts forecast that Cabaletta Bio, Inc. will post -1.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CABA shares. Wall Street Zen downgraded shares of Cabaletta Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 17th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Cabaletta Bio in a research note on Tuesday, September 1st. William Blair upgraded shares of Cabaletta Bio to a “strong-buy” rating in a research report on Wednesday, September 23rd. TD Cowen raised shares of Cabaletta Bio to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cabaletta Bio presently has a consensus rating of “Moderate Buy” and an average target price of $15.60.

Get Our Latest Analysis on Cabaletta Bio

Cabaletta Bio Profile

(Free Report)

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.